Cachexia as a major underestimated and unmet medical need: facts and numbers by von Haehling, Stephan & Anker, Stefan D.
EDITORIAL
Cachexia as a major underestimated and unmet medical
need: facts and numbers
Stephan von Haehling & Stefan D. Anker
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Cachexia is a serious, however underestimated
and underrecognised medical consequence of malignant
cancer, chronic heart failure (CHF), chronic kidney disease
(CKD), chronic obstructive pulmonary disease (COPD),
cystic fibrosis, rheumatoid arthritis, Alzheimer's disease,
infectious diseases, and many other chronic illnesses. The
prevalence of cachexia is high, ranging from 5% to 15% in
CHF or COPD to 60% to 80% in advanced cancer. By
population prevalence, the most frequent cachexia subtypes
are in order: COPD cachexia, cardiac cachexia (in CHF),
cancer cachexia, and CKD cachexia. In industrialized
countries (North America, Europe, Japan), the overall
prevalence of cachexia (due to any disease) is growing
and currently about 1%, i.e., about nine million patients.
The relative prevalence of cachexia is somewhat less in
Asia, but is a growing problem there as well. In absolute
terms, cachexia is, in Asia (due to the larger population), as
least as big a problem as in the Western world. Cachexia is
also a big medical problem in South America and Africa, but
data are scarce. A consensus statement recently proposed to
diagnose cachexia in chronic diseases when there is weight
lossexceeding5% withinthe previous 3–12 months combined
with symptoms characteristic for cachexia (e.g., fatigue), loss
of skeletalmuscle and biochemicalabnormalities (e.g., anemia
or inflammation). Treatment approaches using anabolics,
anti-catabolic therapies, appetite stimulants, and nutritional
interventions are under development. A more thorough
understandingofthepathophysiologyofcachexiadevelopment
and progression is needed that likely will lead to combination
therapies being developed. These efforts are greatly needed as
presence of cachexia is always associated with high-mortality
and poor-symptom status and dismal quality of life. It is
thought that in cancer, more than 30% of patients die due to
cachexia and more than 50% of patients with cancer die with
cachexia being present. In other chronic illnesses, one can
estimate that up to 30% of patients die with some degree of
cachexia being present. Mortality rates of patients with
cachexia range from 10% to 15% per year (COPD), to 20%
to 30% per year (CHF, CKD) to 80% in cancer.
1 Cachexia over the centuries
Cachexia has been known for centuries. Hippocrates wrote
that “the flesh is consumed and becomes water,... the
abdomen fills with water, the feet and legs swell, the
shoulders, clavicles, chest, and thighs melt away... The
illness is fatal.” [1] The term cachexia has Greek roots, a
combination of the words kakós (bad) and hexis (condition
or appearance) [2]. It is not exactly clear who suggested to
use the term cachexia to describe involuntary weight loss in
the context of chronic illness, but the first written documen-
tation of cardiac cachexia, for example, dates back to 1860
when Charles Mauriac, a French physician, described a
“commonly observed secondary phenomenon in patients
affected with diseases of the heart... a peculiar state of
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2 J Cachexia Sarcopenia Muscle (2010) 1:1–5cachexia which is... conventionally designated cardiac
cachexia” [2]. He was not the only one to acknowledge the
importance of body wasting. Herta Müller, winner of the
2009 Nobel Prize for literature, wrote that “once the flesh has
disappeared from the body, carrying the bones becomes a
burden; it draws you down into the earth [3]”.
1.1 Why a new journal?
Given the fact that cachexia has been known for such a
long time, why do we think that the time is ripe to publish a
new journal, the Journal of Cachexia, Sarcopenia and
Muscle? Cachexia is a serious, however underestimated and
underrecognised medical problem that is observed as a
consequence of malignant cancer, chronic heart failure
(CHF), chronic kidney disease (CKD), chronic obstructive
pulmonary disease (COPD), cystic fibrosis, rheumatoid
arthritis, Alzheimer's disease, infectious diseases, and many
other chronic illnesses. Death normally ensues when weight
loss exceeds 30% [4], and it has been estimated that about
50% of patients with cancer have some degree of cachexia
at the time of their death [5]. In starvation, weight loss
exceeding 40% of body weight is not compatible with life
[6]. Neither do we understand the pathophysiology of
cachexia in its entirety, nor do we have approved treatments
against involuntary weight loss other than appetite stimu-
lants (http://www.drugs.com/pro/megestrol.html) and re-
combinant human growth hormone (somatropin; http://
www.drugs.com/pro/serostim.html) in AIDS-associated
body wasting. We believe that cachexia requires more
attention, not only by physicians and other health care
professionals, but also by the general public. Indeed, body
weight is a dynamic parameter and has a certain rhythm
over the lifespan [7], and public opinion is currently more
concerned with weight gain than with weight loss. Public
awareness in chronic diseases needs to be redirected, and
people need to understand that weight gain may be
beneficial in certain clinical situations.
1.2 What is cachexia?
An important consideration in understanding and managing
cachexia is that many misconceptions exist with regards to
weight loss. Laviano and colleagues recently suggested
somewhat depressingly that cachexia represents a state in
which “all you can eat is yourself” [8]. On the other hand,
descriptive terms such as “cachexia”, “anorexia”, “sarcope-
nia”, “malnutrition” and even “hypercatabolism” are frequent-
ly regarded as synonyms by researchers and clinicians [9].
Whilst malnutrition is reversible when adequate amounts of
food are provided, cachexia is not treatable by this approach.
Indeed, cachectic patients usually present with progressive
weight loss along with body composition alterations and
disturbed homeostasis of many body systems, particularly of
fat tissue and muscle [4, 9, 10]. In fact, loss of fat tissue
appears to be similar important in the pathophysiology of
cachexia like loss of muscle even though fat, unlike muscle,
cannot generate its own thermic energy. Rheumatoid
arthritis may be an exeption to the rule of weight loss
being the defining feature of cachexia. In rheumatoid
arthritis loss of fat-free mass is often accompanied by
increased fat mass and therefore stable body weight [11].
A final common pathway of body wasting has not been
established as yet, but evidence suggests that activation of
neuroendocrine and inflammatory systems, increased
lipolysis, lack of appetite and malabsorption all play a
role [4, 9, 10]. Overall, an anabolic–catabolic dysbalance
exists although the mechanisms of weight loss appear to differ
between clinical syndromes: Whilst in cachectic patients with
cancer or COPD a reduction in muscle protein synthesis plays
a prominent role, in heart failure-associated cardiac cachexia,
there is incrased muscle protein breakdown and reduced
synthesis [10, 12].
Cachexia has been described in many different chronic
illnesses. The prevalence of cachexia is high, ranging
from 5% to 15% in advanced CHF or COPD to 60% to
80% in advanced cancer (Table 1). When one calculates
the population prevalence of cachexia, it can be estimated
that the most frequent cachexia subtypes are in order:
COPD cachexia, cardiac (CHF) cachexia, cancer cachexia
and CKD cachexia. In industrialized countries (North
America, Europe, Japan), the overall prevalence of
cachexia (due to any disease) is growing and currently
about 1%, i.e., about nine million patients. The relative
prevalence of cachexia is somewhat less in Asia, but is a
growing problem also in Asianc o u n t r i e sa n di na b s o l u t e
terms (due to the larger population) as least as big a
problem as in the Western world. Data on cachexia in
South America and Africa are scarce, but the cachexia
problem is big in these continents too. For many of the
illnesses in which cachexia may ultimately develop,
clinicians do not “automatically” sense an association
with involuntary weight loss. Additionally, researchers
have used various definitions to describe cachexia
(Table 1), which not only yielded difficulties in comparing
study results but also uncertainty as to whether or not the
diagnosis of cachexia should be made in clinical practice.
These unsatisfying circumstances have made the need for
a standardized definition of cachexia paramount in recent
years [13, 14].
1.3 Defining a frequent clinical problem
Many definitions used in studies of cachexia in different
illnesses have focused on weight loss alone, and few
acknowledged the importance of body composition or
J Cachexia Sarcopenia Muscle (2010) 1:1–5 3temporal components of weight change. In cardiac cachexia,
for example,itis necessary toconsiderthe presenceofedema,
and only non-edematous weight loss can be considered
appropriate [15]. Changes in body composition are not easily
detectable, and may require even advanced technologies such
as dual energy X-ray absorptiometry. This has to be
considered when proposing a definition of cachexia that
should be easily applicable in clinical settings.
In addition to the above, the definition of cachexia
should not only pick up manifest cachexia but also identify
patients at risk of developing this syndrome. A consensus
meeting was recently held to define cachexia, finally
reaching a clinical definition that can be applied in almost
any clinical entity. It was eventually published in 2008 [16].
Weight loss is at the forefront of that definition, and it was
agreed to diagnose cachexia in chronic diseases when there
is weight loss exceeding 5% within the previous 3–
12 months combined with symptoms characteristic for
cachexia (e.g., fatigue), loss of skeletal muscle, and
biochemical abnormalities (e.g., anemia or inflammation)
[16]. The criteria together with the full definition of
cachexia are given in Table 2. When applying this tool in
clinical practice, however, it has to be kept in mind that the
new definition has not been evaluated for its clinical
usefulness or its value as a prognostic marker. Such studies
are under way.
Currently, no specific treatment is available for cachectic
patients. Treatment approaches using anabolics, anti-
catabolic therapies, appetite stimulants, and nutritional
interventions are under development [9]. Indeed, many
different approaches have been investigated in clinical
studies; however, many of them were hampered by small
sample size. A more thorough understanding of the patho-
physiology of cachexia development and progression is
needed that likely will lead even to combination therapies
being developed. These efforts are greatly needed as the
presence of cachexia is always associated with a high-
mortality and poor-symptom status and dismal quality
of life.
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